改良中药剂型芪参扶正胶囊对晚期非小细胞肺癌表皮生长因子受体未突变化疗患者生存质量影响的临床研究  

Clinical study on the effect of the Qishen Fuzheng capsule on the quality of life of patients with advanced non-small cell lung cancer without EGFR mutation during chemotherapy

作　　者：张永杰[1] 殷江霞[1] 李爱香[1] 张子志 ZHANG Yongjie;YIN Jiangxia;LI Aixiang;ZHANG Zizhi

机构地区：[1]寿光市中医医院,山东潍坊262700

出　　处：《中医临床研究》2022年第9期105-107,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:研究改良中药剂型在提高晚期非小细胞肺癌化疗患者的生活质量方面的优势。方法:选取寿光市中医医院肿瘤一科2019年6月-2020年7月采用多西他赛和顺铂化疗方案的晚期非小细胞肺癌表皮生长因子受体未突变患者,按1∶1的奇偶比例分组,对照组采用多西他赛和顺铂方案化疗,治疗组采用芪参扶正胶囊加DP化疗方案。结果:治疗组患者在生活质量评价量表评分、Karnofsky功能状态评分法(Karnofsky Performance Status,KPS)评分、中医证候评分方面有明显改善;治疗组中体质量较治疗前增加,差异有统计学意义;治疗组白细胞及血小板数值明显好于对照组,差异具有统计学意义。结论:改良中药剂型芪参扶正胶囊具有改善脾肾亏虚型晚期非小细胞肺癌患者的生活质量,增加体质量,减轻化疗药物骨髓抑制的综合疗效。Objective:To study the advantages of improved traditional Chinese medicine dosage form on the quality of life of patients with advanced non-small cell lung cancer during chemotherapy.Methods:According to the plan of DP chemotherapy in the first Department of Oncology,Shouguang Hospital of Traditional Chinese Medicine from June 2019 to July 2020,the patients were divided into the control group and the treatment group by 1∶1 parity ratio.The control group was treated by DP chemotherapy,while the treatment group was treated with the Qishen Fuzheng capsule(芪参扶正胶囊)plus DP chemotherapy.Results:The QOL score,KPS score and TCM syndrome score in the treatment group were significantly improved;the body weight in the treatment group was increased compared with that before treatment,and the difference was statistically significant.WBC and platelets in the treatment group were significantly better than those in the control group,which was with statistical difference.Conclusion:The Qishen Fuzheng capsule can improve the quality of life of patients with advanced non-small cell lung cancer of spleen and kidney deficiency type,increase body weight,and reduce myelosuppression due to chemotherapy drug.

关 键 词：改良中药剂型 芪参扶正胶囊 非小细胞肺癌 临床研究 

分 类 号：R273[医药卫生—中西医结合]